Corporate Presentation
Obesity
Dapiglutide
In H2 2024, results for dapiglutide are expected
from the 13-week Phase 1b dose-titration trial
ZEAL&
ZEALAND PHARMA
The Phase 1b trial is evaluating higher doses of dapiglutide than the previous 4-week MAD trial and DREAM
ÅÅÅ
ÅÅÅÅÅ
Population
N=54, men and women aged 18-64 years
BMI 27.0-39.9 kg/m²
Duration
13 weeks
Dose
strengths
Higher doses than the previous 4-week MAD trial and DREAM
Endpoints
Primary endpoint: incidence of TEAES
Key secondary endpoints: pharmacokinetics endpoints related to dapiglutide exposure;
absolute and percentage change in body weight from baseline to Day 92
Source: ClinicalTrials.gov (NCT06000891), accessed November 2023.
BMI-body mass index; MAD=multiple ascending dose; TEAE-treatment-emergent adverse event.
23View entire presentation